时近2025年尾声，医药领域风起云涌，多家药企正通过战略合作加速整合资源，进一步聚焦细分赛道领 域。近期，康哲药业(00867.HK)宣布与全球制药巨头诺华签署经销协议，获得诺华就雷珠单抗注射液 (诺适得)、布西珠单抗注射液(倍优适)两款眼科药物在中国大陆的独家进口、经销、销售、推广权利。 此次合作不仅是康哲药业在眼科领域的重磅加码，更彰显了其深耕专科疾病领域的发展决心。 这一战略眼光同样体现在其对皮肤健康赛道的布局上。在六个月前，康哲药业推动旗下皮肤健康业务 ——德镁医药有限公司(以下简称：德镁医药)向港交所递交上市申请，助力其更好地聚焦核心业务。这 家从康哲药业分拆而来的公司，正凭借专业聚焦，挖掘皮肤健康高增长专科赛道的潜力。 在皮肤病诊疗需求持续升级的背景下，自身免疫性皮肤病、炎症性皮肤病等高发疾病领域备受市场关 注，其中白癜风、银屑病、特应性皮炎、痤疮四大细分领域因患者基数庞大、治疗方案有限，成为医药 企业竞争的核心战场。 面对特应性皮炎这一快速增长的市场，德镁医药采取了多管线布局策略。除芦可替尼乳膏正在开展治疗 轻中度特应性皮炎的新药上市申请工作外，德镁医药还拥有MG-K10，一款新型的长效(每四周 ...

Core Viewpoint - The article highlights the widespread issue of acne among adolescents in China, emphasizing the psychological and social impacts it has on individuals, and the need for timely and effective treatment rather than the common misconception that it is a normal part of growing up [19][21]. Group 1: Prevalence and Impact of Acne - A study indicates that 95% of individuals experience some degree of acne, with 3% to 7% of patients developing scars [1]. - Many adolescents face self-esteem issues and social anxiety due to acne, which can affect their personal and professional lives [1][19]. Group 2: Treatment Challenges - Parents often resort to ineffective home remedies or delay seeking professional help, believing that acne will resolve on its own [19][21]. - The article discusses various treatment experiences, including the use of topical medications and oral antibiotics, which often come with side effects and limited effectiveness [20]. Group 3: Psychological Effects - Acne can lead to significant emotional distress, with many individuals feeling self-conscious and avoiding social interactions [19][21]. - The stigma associated with acne can exacerbate feelings of isolation and anxiety among affected adolescents [19]. Group 4: Need for Awareness and Education - There is a lack of understanding about acne among the general population, with 60.4% of people not fully aware of the condition [19]. - The article calls for increased awareness and education for both parents and adolescents regarding the importance of early intervention and proper treatment [21]. Group 5: Advances in Treatment - Recent guidelines and advancements in acne treatment are being introduced, aiming to provide safer and more effective options for patients [20]. - The introduction of new technologies and treatment methods is seen as a positive step towards addressing the acne epidemic among youth [20].

Company Overview - 德镁医药 is an innovative pharmaceutical company focused on skin health, operating under 康哲药业. It specializes in prescription drugs and dermatological skincare products, with three products already on the market and several candidates in various clinical stages [1] Financial Performance - Revenue for 2023 reached RMB 472.56 million, a year-on-year increase of 23.2%, driven by a robust growth in prescription drugs and a significant surge in skincare products [2][3] - Prescription drug revenue was RMB 424.82 million in 2023, up 13.6% from RMB 374.04 million in 2022, accounting for 89.9% of total revenue [2] - Skincare product revenue skyrocketed by 404.4% to RMB 47.74 million in 2023, primarily due to successful e-commerce promotions [3] Profitability and Margins - The overall gross margin improved to 76.9% in 2023, up 6.8 percentage points from the previous year, with a significant reduction in net loss to RMB 5 million [5] - The gross margin for prescription drugs was 76.6%, while skincare products achieved a gross margin of 79.0% [5] - However, the gross margin is expected to decline to 63.5% in 2024 due to increased costs and pricing pressures from insurance adjustments [7][8] Debt Structure and Cash Levels - A debt-to-equity conversion in 2024 significantly improved the company's balance sheet, reducing liabilities from RMB 15.75 billion to RMB 1.54 billion [10] - Despite the reduction in debt, cash reserves remain tight, with only RMB 2.82 billion available at the end of 2024 [10] Competitive Advantages - 德镁医药 has the broadest coverage of skin disease indications in China, with nine conditions addressed, surpassing competitors [11] - Key products like 益路取 for psoriasis and 喜辽妥 for scar treatment have unique advantages, including insurance coverage and lack of direct competition [12][14] - The company benefits from a strong distribution network, leveraging 康哲药业's existing relationships with over 10,000 hospitals and 100,000 pharmacies [13] Industry Context - The Chinese skin treatment and care market was valued at RMB 76.4 billion in 2023, with a projected CAGR of 10.6% through 2035, driven by the high prevalence of chronic skin diseases [20] - The demand for dermatological skincare products is also increasing, with significant growth in e-commerce channels [20]

Core Insights - The article emphasizes the importance of diet in maintaining skin health, highlighting that collagen is crucial for skin elasticity and smoothness. As people age, their natural collagen production declines due to various factors, including stress and poor diet [1] Food Sources of Collagen - Bone broth is rich in collagen, gelatin, and essential amino acids, promoting collagen production and skin health [2] - Fatty fish like salmon and tuna are excellent sources of omega-3 fatty acids and marine collagen, which enhance skin elasticity and hydration [3] - Eggs, while not containing collagen directly, are rich in proline and lysine, amino acids vital for collagen synthesis [4] - Citrus fruits are high in vitamin C, essential for stabilizing and generating collagen molecules [5] - Berries contain antioxidants and vitamin C, which are important for collagen production and skin protection [6] - Leafy greens are nutrient-dense and support collagen synthesis while protecting the skin from damage [7] - Nuts and seeds provide omega-3 fatty acids and zinc, crucial for collagen production and skin repair [8] - Garlic contains sulfur, which is necessary for collagen production and helps rebuild damaged collagen fibers [9] - Tomatoes are rich in lycopene, an antioxidant that protects the skin from UV damage and supports collagen synthesis [10] - Avocados provide healthy fats and vitamins E and C, essential for collagen production and skin health [11] - Soy products are excellent sources of plant protein and isoflavones, supporting collagen production and improving skin elasticity [12] - Kiwi has a high vitamin C content, aiding in collagen formation and providing antioxidants for skin health [13] - Pumpkin seeds are rich in beta-carotene, vitamin C, and zinc, all important for collagen synthesis and skin repair [14] - Cashews are high in copper, which is vital for collagen connection and maintaining skin elasticity [15] - Colorful bell peppers are rich in vitamin C and antioxidants, helping to reduce inflammation and protect the skin [16] - Mushrooms, especially sun-exposed varieties, are a rare plant source of vitamin D, crucial for collagen integrity [17]

Core Viewpoint - The increasing prevalence of skin health issues among the elderly in China is evolving from a cosmetic concern to a significant public health crisis, particularly highlighted by the rising incidence of shingles [1][2]. Group 1: Skin Health Challenges - There are over 2,000 named skin diseases, making dermatology one of the most complex medical fields [2]. - The incidence of skin diseases in China is alarmingly high, with a prevalence rate of 40%-70%, leading to significant health-related quality of life losses [2]. - Shingles, a disease that significantly increases in incidence with age, affects about one-third of individuals in their lifetime, with approximately 600,000 new cases annually in China, of which 1.56 million are in individuals over 50 [2]. Group 2: Chronic Diseases and Shingles - Patients with chronic diseases such as diabetes and cardiovascular conditions have a 26%-41% higher risk of developing shingles compared to the general population [2][3]. - The presence of shingles can exacerbate existing chronic conditions and increase the risk of severe pain, leading to a higher likelihood of depression and anxiety among affected individuals [3]. Group 3: Awareness and Prevention - There is a significant gap in awareness and preventive measures regarding shingles among the elderly, with over 60% believing they are not at risk [4]. - A study indicates that 30% of patients delay treatment due to the misconception that they can endure the pain [4]. - Effective public health education is essential to shift the mindset from "enduring pain" to "proactive prevention," emphasizing the importance of vaccination and early intervention [4][5]. Group 4: Community Health Initiatives - Community health service centers are crucial in addressing these health trends, particularly in managing chronic diseases and their complications [3][5]. - New models of integrated medical and preventive care are being explored, such as the introduction of public health physician prescriptions to enhance preventive measures [5]. - Trust in healthcare providers, particularly family doctors, is vital for encouraging residents to engage in preventive health actions, including vaccinations [5].

Core Viewpoint - 康哲药业 plans to spin off its skin health subsidiary, 德镁医药, and list it on the Hong Kong main board through a distribution of shares to existing shareholders, without diluting their equity [1] Group 1: Company Overview - 德镁医药 focuses on skin health and is responsible for 康哲药业's domestic skin health business, providing comprehensive solutions from prevention to long-term care [1] - The company has incurred losses during the performance record period due to ongoing investments in business development, which aligns with the growth logic of a developing enterprise [1] Group 2: Product Pipeline and Market Position - 德镁医药's product pipeline includes three marketed products, four candidates in clinical or late-stage trials, and two preclinical candidates, covering major skin diseases such as psoriasis, vitiligo, and atopic dermatitis [2] - The company ranks first among Chinese innovative pharmaceutical companies in terms of the number of skin disease indications covered by products in late-stage clinical trials or commercialization [2] - Notable products include the innovative drug, 芦可替尼乳膏, which targets the unapproved treatment area of vitiligo, and the commercialized drug IL-23益路取, which is penetrating the psoriasis market [1][2]

Core Viewpoint - The article discusses the emergence of Demy Pharmaceutical, a subsidiary of Kangzhe Pharmaceutical, focusing on the development and market potential of the drug "Ruxolitinib Cream" for treating vitiligo, amidst a growing demand for effective skin health products in China [1][2]. Company Overview - Demy Pharmaceutical is set to independently list in Hong Kong, having submitted its prospectus in April 2023, and is positioned to capitalize on the skin health market, which is projected to be worth billions [1][2]. - The company has a strong product pipeline, including Ruxolitinib Cream, which is the only FDA-approved JAK inhibitor for vitiligo, and other skin-related products [3][5]. Market Potential - There are over 10 million vitiligo patients in China, and the market for effective treatments is largely untapped, with Ruxolitinib Cream expected to generate significant revenue, projected at $340 million in its first full sales year [4][10]. - The skin health market is characterized by a high demand for unique and effective treatments, with Demy focusing on products that have a strong market need and limited competition [7][11]. Financial Performance - Demy Pharmaceutical has shown promising financials, with revenues expected to exceed 600 million yuan in 2024, reflecting a growth trend in the skin health segment [2][7]. - The company has maintained a positive cash flow despite not yet being profitable, indicating strong market interest and potential for future growth [2][10]. Product Pipeline - The product pipeline includes several other skin prescription drugs, with a focus on unique and differentiated products that address significant medical needs [5][7]. - The company has successfully introduced products that are the only approved treatments for specific conditions in China, enhancing its competitive edge [7][11]. Sales Strategy - Demy Pharmaceutical's sales strategy emphasizes leveraging its parent company's marketing expertise and established distribution channels, with a focus on hospital and retail pharmacy coverage [10][12]. - The company has a strong commercial team, with over 85% of its workforce dedicated to sales, which is crucial for its growth in the competitive biopharmaceutical market [10][12].